Clinical trial inclusion in patients with relapsed/refractory neuroblastoma following the European Precision Cancer Medicine trial MAPPYACTS

This study aimed to explore the impact of molecular profiling within the prospective precision cancer medicine trial MAPPYACTS (NCT02613962) on subsequent early phase trial recruitment and treatment by matched targeted therapies in this population.

Source: European Journal of Cancer - February 14, 2024 Category: Cancer & Oncology Authors: Jordane CHAIX, Gudrun SCHLEIERMACHER, Nad ège CORRADINI, Nicolas ANDRE, Estelle THEBAUD, Marion GAMBART, Anne-Sophie DEFACHELLES, Natacha ENTZ-WERLE, Pascal CHASTAGNER, Émilie DE CARLI, Stéphane DUCASSOU, Judith LANDMAN-PARKER, Tiphaine ADAM-DE-BEAUMAI Tags: Original Research Source Type: research